Alexander Joost

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

Clopidogrel with or without Omeprazole in Coronary Artery Disease

Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel

Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”

Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention††Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker’s bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received research grants from Sanofi-Aventis.

Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)

Variability in Individual Responsiveness to Clopidogrel

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

Perioperative Management of Antithrombotic Therapy

Cyphering the Complexity of Coronary Artery Disease Using the Syntax Score to Predict Clinical Outcome in Patients With Three-Vessel Lumen Obstruction Undergoing Percutaneous Coronary Intervention

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome

Impact of P-glycoprotein on clopidogrel absorption

The Year in Non-ST-Segment Elevation Acute Coronary Syndromes

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product

Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention

The Year in Non–ST-Segment Elevation Acute Coronary Syndrome

Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics<SUBTITLE>The PCI-CLARITY Study</SUBTITLE>

Guidelines for Percutaneous Coronary Interventions

The Perioperative Management of Antithrombotic Therapy

Clopidogrel Loading Dose (300 Versus 600 mg) Strategies for Patients With Stable Angina Pectoris Subjected to Percutaneous Coronary Intervention

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease

Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation

The inflammatory response in myocardial injury, repair, and remodelling

Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease

Development and validation of a dissolution test with reversed-phase high performance liquid chromatographic analysis for Candesartan cilexetil in tablet dosage forms

Novel Role of Platelets in Mediating Inflammatory Responses and Ventricular Rupture or Remodeling Following Myocardial Infarction

2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines

Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel

Guidelines for the Primary Prevention of Stroke

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”

Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

Systematic review of exercise training or percutaneous transluminal angioplasty for intermittent claudication

Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

Candesartan cilexetil: an update

Drug eluting balloons for the treatment of coronary artery disease: What can we expect?

Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy